Partnership Seeks to Lower Barriers to Evidence-Based Molecular Oncology Care by Extending Trapelo’s Decision Support Solutions Through Concert’s Network of Laboratories and Health Plans
BURLINGTON, MA and NASHVILLE, TN (Dec. 10, 2020) – Concert Genetics and Trapelo Health announced today that they have partnered to provide a streamlined, integrated solution that will expand access to evidence-based, genomic-informed oncology decision support.
The partnership is built on a shared mission to improve connectivity, transparency, and alignment among the healthcare stakeholders that support the delivery of oncology care. It combines the unique strengths of the two organizations: Concert’s genetic testing data and digital infrastructure and Trapelo’s expertise in molecular oncology decision support.
BURLINGTON, MA – March 10, 2020: Clynt Taylor, CEO of Intervention Insights, announced this week that the company has officially changed its name to Trapelo Health. Taylor explained that the new name reflects a commitment to the company’s platform, Trapelo, which launched in December 2018.
Trapelo represents an evolution of Intervention Insights’ capabilities, which are built on a continuously updated, data-driven knowledgebase of published clinical literature and precision medicine data. The first-of-its-kind, technology platform unites oncologists, molecular labs, and payers around the goals of improving patient outcomes and managing costs by providing real-time decision support for testing and treatment selection at the point of care.
Mr. Burrell brings cross-sector experience championing value-based healthcare to Intervention Insights’ collaborative, precision medicine platform, Trapelo.™
BURLINGTON, MA – July 25, 2019: Intervention Insights welcomes respected healthcare leader Chet Burrell as its Executive Chairman to support the continued growth of its distinct, precision diagnostic platform Trapelo.
Chet Burrell is the founder and managing member of Silavon Healthcare Holdings, where he oversees highly selective investments in U.S healthcare companies that are believed to offer both high social-impact and high investment value.
The distinguished healthcare innovator and former business leader for major health groups brings both payer and provider perspectives to support the collaborative, precision medicine platform, Trapelo.™
BURLINGTON, MA – May 28, 2019: Intervention Insights announces the appointment of Dr. Lee Newcomer, former UnitedHealthcare executive and Medical Director for Cigna Healthcare, to its Board of Directors to support the growth of its distinct, precision medicine platform Trapelo.
Intervention Insights’ first-of-its-kind, decision support, order management and results reporting solution for molecular testing enables real-time alignment among oncologists, labs and payers in the dynamic and increasingly complex world of precision medicine.
BURLINGTON, MA – November 27, 2018: Intervention Insights is collaborating with City of Hope, a world-renowned independent cancer research and treatment center, to advance the appropriate use of precision medicine in oncology. By working with Intervention Insights and leveraging Trapelo™, its evidence-based technology platform, the organization will demonstrate new ways to incorporate precision medicine decision support at the point of care.
Trapelo™ enables oncologists to identify in real time the right patients for molecular testing and the right tests to perform by preferred labs for actionable results that lead to faster, more targeted treatment choices when time matters most.
WALTHAM, MA – December 7, 2017: Intervention Insights is pleased to announce the availability of Trapelo, a true advancement in the use of molecular science and targeted therapies for cancer patients. The first-of-its-kind, decision support, order management and results reporting solution for molecular testing enables real-time alignment among oncologists, labs and payors in the dynamic and increasingly complex world of precision medicine.